ARECOR THERAPEUTICS PLC (AREC) — Arecor Interim Results, Co-development Agreement & Sale of Royalty and Technology Access Fees

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the ARECOR THERAPEUTICS PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time via the Q and A tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and we'll publish our responses where it's appropriate to do so on the Investor Meet company platform. Before we begin, we would just like to submit the following poll. And if you could give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the executive management team from ARECOR THERAPUITIX PLC. Sarah, good morning. Good morning. Thank you, Mark. So good morning, everybody. Thank you for taking the time to join us today. My name is doctor Sarah Howell, and I'm the CEO of ARECOR THERAPEUTICS, and I'm joined today by David Ellum, our CFO. And we'll talk you through today ARECOR's interim results for the six months ending 06/30/2025 and also some significant events and deals and news flow that you may have seen that we announced with our results last week. So I'll draw your attention to our customary legal notice. So just as a little bit of a recap, ARECOR is a clinical stage biopharmaceutical company very much focused on drug development and delivery for diabetes and other cardiometabolic diseases. We have our own proprietary product portfolio where we're targeting areas of significant unmet patient needs, in high value markets, very much in the diabetes and obesity space....